retatrutide clinical trials phase 2 Obesity is expected to affect nearly a quarter of the world population by 2035. Retatrutide, an investigational GIP, GLP-1, and GCG receptor agonist, holds promise for weight reduction in adults. New Triple hormone receptor agonist retatrutide
Pay in 4 interest-free payments of $5.50 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23








.png.jpg)





















